Cardiac allograft vasculopathy remains a major challenge to long-term survival after heart
transplantation. Endothelial injury and dysfunction, as a result of multifactorial immunologic …

Immunosuppression after heart transplantation has significantly reduced the incidence of
cellular rejection and improved patient outcomes with the routine use of calcineurin …

Associated with technological progress in deoxyribonucleic acid and messenger ribonucleic
acid profiling, advances in basic biology have led to a more complete and sophisticated …

Heart transplantation remains the most durable treatment for end-stage heart disease that is
not amenable to coronary revascularization or anti-arrhythmic therapies. Cardiac allograft …

Objectives The authors sought to evaluate cardiac activity of angiotensin-converting enzyme
(ACE) and ACE2 after heart transplantation (HT) and its relation with acute rejection (AR) …

The use of angiotensin‐converting enzyme inhibitors is an important therapy for various
cardiovascular diseases, such as hypertension, ischemic heart disease and heart failure …

Cardiac allograft vasculopathy (CAV) is a major cause of death in patients surviving more
than 1 year after heart transplantation. An important cluster of CAV risk factors occurs as a …

The field of heart transplantation was built upon the discoveries of immunity and tolerance
by Landsteiner, Medawar, Burnet, and others, as well as technical advancements in surgical …

Nowadays long-term outcome of heart transplantation is limited by a peculiar type of
coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact …

Objectives: This study sought to investigate the influence of recipient renin-angiotensin-
aldosterone system (RAAS) genotype on cardiac function, rejection, and outcomes after …